Virtuix partners with Sirica to deploy Omni One systems for autism therapy at a Bay Area treatment center, targeting nationwide expansion.
Quiver AI Summary
Virtuix Holdings Inc. has announced a partnership with Sirica Therapeutics to deploy its Omni One systems at Sirica's first autism treatment center in the San Francisco Bay Area. This initiative aims to enhance autism therapy through movement-centered virtual reality and AI-assisted experiences, aligning with Sirica's plans to create 100 autism treatment centers nationwide. The collaboration builds on research from Rutgers University and positions Virtuix's technology, which facilitates natural movement in virtual environments, within the healthcare sector. This partnership emphasizes a commitment to using immersive simulation technology to improve therapeutic outcomes for children with autism and related disorders. Both companies are dedicated to innovating in autism care, with Sirica's unique Cognitive Sensory Motor therapy aiming to address the needs of individuals on the autism spectrum.
Potential Positives
- Virtuix has successfully deployed its Omni One platform in collaboration with Sirica Therapeutics, marking a significant step into immersive autism therapy applications.
- The partnership signals Virtuix's strategic expansion into the healthcare sector, particularly in innovative therapies for autism, which aligns with ongoing research initiatives at universities.
- Sirica Therapeutics plans to establish approximately 100 treatment centers across the United States, potentially amplifying Virtuix's market presence and impact on patient care in autism therapy.
Potential Negatives
- Virtuix may face skepticism regarding the unproven efficacy of its technology in clinical settings due to a lack of published research data supporting the benefits of the Omni One platform for autism therapy.
- The company's ambitious plans to establish 100 treatment centers could strain resources and lead to operational challenges, potentially impacting service quality and financial performance.
- The reliance on forward-looking statements about growth and market position may create investor unease, particularly if future results do not meet expectations.
FAQ
What is the Omni One system used for?
The Omni One system is used for immersive autism therapy applications, enhancing engagement and treatment outcomes for children with autism.
How many autism treatment centers does Sirica plan to open?
Sirica plans to establish approximately 100 autism treatment centers across the United States as part of its national expansion.
What technology does the Omni One platform utilize?
The Omni One platform utilizes movement-centered virtual reality and AI-assisted therapeutic experiences to support autism therapy.
Who are the partners in this collaboration?
This collaboration is between Virtuix Holdings Inc. and Sirica Therapeutics, aimed at advancing autism therapy through innovative technology.
What is the goal of Sirica Therapeutics?
Sirica Therapeutics aims to create a new model of care for autism, improving the quality of life for individuals through innovative therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VTIX Insider Trading Activity
$VTIX insiders have traded $VTIX stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $VTIX stock by insiders over the last 6 months:
- JAN ROGER GOETGELUK (Chief Executive Officer) has made 0 purchases and 18 sales selling 479,721 shares for an estimated $2,521,394.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$VTIX Hedge Fund Activity
We have seen 19 institutional investors add shares of $VTIX stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 307,519 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,081,903
- GEODE CAPITAL MANAGEMENT, LLC added 247,841 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,677,883
- MILLENNIUM MANAGEMENT LLC added 238,915 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,617,454
- BANK OF AMERICA CORP /DE/ added 52,277 shares (+inf%) to their portfolio in Q1 2026, for an estimated $353,915
- INSIGHT WEALTH PARTNERS, LLC added 48,298 shares (+inf%) to their portfolio in Q1 2026, for an estimated $326,977
- GOLDMAN SACHS GROUP INC added 46,441 shares (+inf%) to their portfolio in Q1 2026, for an estimated $314,405
- NORTHERN TRUST CORP added 45,690 shares (+inf%) to their portfolio in Q1 2026, for an estimated $309,321
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
Initial Deployment Brings Omni One Systems to Sirica's First Bay Area Treatment Center
Collaboration Builds on Rutgers University Research and Advances Sirica's Plan to Establish 100 Autism Treatment Centers Nationwide
AUSTIN, Texas, July 07, 2026 (GLOBE NEWSWIRE) -- Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of AI-driven, full-body simulation systems, today announced a strategic partnership with Sirica Therapeutics to deploy its Omni One platform for immersive autism therapy applications.
As part of the collaboration, Virtuix has sold and shipped the first two Omni One systems to Sirica's treatment center in the San Francisco Bay Area. The companies intend to use movement-centered virtual reality and AI-assisted therapeutic experiences to enhance engagement and treatment outcomes for children with autism and related disorders. Sirica has announced plans to establish approximately 100 Sirica Centers across the United States, creating a nationwide network of specialized autism treatment facilities.
The partnership represents another important milestone in Virtuix's expansion into healthcare applications following its recently announced research collaboration with Rutgers University to explore AI-assisted neurodivergent therapy using the Omni One platform and its collaboration with Florida Gulf Coast University using Omni One for neurological rehabilitation. These initiatives advance Virtuix’s strategy to extend its immersive simulation platform into clinical environments where movement-based technologies may enhance patient engagement and therapy efficacy.
“We believe AI-driven, full-body immersive simulation has the potential to transform how behavioral therapies are delivered,” said Jan Goetgeluk, Founder and CEO of Virtuix. “Our collaboration with Sirica Therapeutics represents an exciting step toward bringing movement-centered XR into real-world clinical settings. Combined with our ongoing research at Rutgers University and Florida Gulf Coast University, this collaboration reinforces our commitment to advancing innovative healthcare applications for Omni One.”
“We are excited to partner with Virtuix to advance movement-based autism therapy through AI and immersive virtual reality,” said Dr. Uli K. Chettipally, Founder and CEO of Sirica Therapeutics. “At Sirica, our vision is to create a new model of care for autism and neurodiversity. Our Cognitive Sensory Motor (COSMO) therapy harnesses purposeful movement, sensory engagement, and cognitive challenge to improve quality of life outcomes. We look forward to partnering with Virtuix as we expand our network of Sirica Centers nationwide.”
Virtuix's AI-driven Omni One platform continues to expand beyond consumer entertainment into healthcare, defense, education, and enterprise applications where natural movement enhances immersive training and simulation. The company's technology enables users to walk, run, crouch, kneel, and turn naturally within virtual environments while remaining safely contained within a compact footprint.
Building on its momentum across healthcare, Virtuix believes movement-centered immersive experiences combined with AI may play an increasingly important role in autism therapy, rehabilitation, and other behavioral health applications. With Sirica's planned national expansion and Virtuix's ongoing university-led research initiatives, the Company believes it is well positioned to participate in the growing adoption of immersive technology across clinical care.
About Virtuix
Virtuix Holdings Inc. (NASDAQ: VTIX) is a leading manufacturer of AI-driven, full-body simulation systems for consumer, enterprise, healthcare, and defense markets. The company’s premier portfolio of “Omni” omni-directional treadmills enables users to walk and run in 360 degrees inside video games and other virtual worlds. With a commitment to innovation, Virtuix continues to push the boundaries of XR, spatial computing, and AI-driven immersive experiences. For more information, visit virtuix.com .
Please visit the Company’s new Investor Relations website at invest.virtuix.com .
About Sirica Therapeutics
Sirica Therapeutics is a digital therapeutics company for Autism and related disorders. The inspiration behind Sirica Therapeutics is Founder & CEO Dr. Uli K. Chettipally's personal experience raising his daughter Siri, who was diagnosed with autism. This life-changing event led him on a journey to find answers and help millions of individuals with similar challenges. We are developing a new category of therapy called Cognitive Sensorimotor Therapy. It uses advanced robotics, virtual reality, and video gaming. The company was founded with the aim of creating a unique and engaging therapeutic device that combines robotics, virtual reality, and video gaming to provide a personalized experience for patients on the autism spectrum. Sirica Therapeutics' mission is to improve the lives affected by autism by offering a deeply immersive and task-oriented therapy that can bring joy and positive change to individuals and families touched by this condition. To learn more please visit www.siricatx.com .
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “could,” “would,” “potential” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s plans to pursue strategic acquisitions, the potential benefits of any such acquisition, the expected synergies, the potential impact on revenues or shareholder value, and the Company’s position in the defense training market. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business; risks related to government contracting, including contract cancellations, modifications, or funding changes; the uncertainties related to market conditions; and other factors discussed in the “Risk Factors” section of the Company’s registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov . The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
Visit Us on Social Media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X
Company Contact
Lauren Premo
Virtuix Inc.
[email protected]
Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
[email protected]
